--- title: "Allarity Therapeutics (ALLR) news: offering and Nasdaq notice" url: "https://aibio.space/companies/allarity-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ALLR offering and Nasdaq notice news: Allarity Therapeutics agrees to $2.5 million private placement of shares and pre-funded warrants." --- ALLR Allarity Therapeutics, Inc. NASDAQ · United States # Allarity Therapeutics (ALLR) news ALLR offering and Nasdaq notice news Financings · 2025-09-22 ## [Allarity Therapeutics agrees to $2.5 million private placement of shares and pre-funded warrants](https://aibio.space/news/allarity-therapeutics-agrees-2-5-million-private-placement-7-5-million/) Allarity agreed to sell 1,562,500 shares at $1.60 each, or pre-funded warrants, to one investor, closing September 23, 2025. The investor may buy $7.5 million more: within 90 days per the 8-K, 60 days per the purchase agreement. ## Latest Allarity Therapeutics news 1. 2025-09-22 Financings [Allarity Therapeutics agrees to $2.5 million private placement, with $7.5 million option](https://aibio.space/news/allarity-therapeutics-agrees-2-5-million-private-placement-7-5-million/) The buyer gets 1,562,500 shares or pre-funded warrants at $1.60 and can add $7.5 million more within 90 days, at a price set by Nasdaq's minimum-price rule. 2. 2025-08-14 Distress [Allarity Therapeutics files NT 10-Q, says June 30, 2025 quarterly report will be late](https://aibio.space/news/allarity-therapeutics-files-nt-10-q-says-june-30-2025-quarterly-report/) Allarity says its auditors have not finished reviewing the quarter. It expects to file within five calendar days of the due date and does not anticipate a significant change in results from a year earlier. 3. 2025-08-14 Distress [Allarity Therapeutics delays quarterly report while auditors finish review](https://aibio.space/news/allarity-therapeutics-delays-quarterly-report-while-auditors-finish/) The company filed a late-filing notice on August 14, 2025 for its report on the quarter ended June 30, 2025. It expects to file within the extension period, but its auditors had not finished their review. ## Allarity Therapeutics at a glance - **Ticker**: ALLR - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $17.0 million ### Related companies - [MERA PHARMACEUTICALS INC](https://aibio.space/companies/mera-pharmaceuticals/) OTC: MRPI - [Ocean Biomediacal](https://aibio.space/companies/ocean-biomediacal/) OTC: OCEA - [Atossa Therapeutics](https://aibio.space/companies/atossa-therapeutics/) NASDAQ: ATOS - [Abeona Therapeutics](https://aibio.space/companies/abeona-therapeutics/) NASDAQ: ABEO - [Arbutus Biopharma](https://aibio.space/companies/arbutus-biopharma/) NASDAQ: ABUS - [Biohaven](https://aibio.space/companies/biohaven/) NYSE: BHVN - [Artelo Biosciences](https://aibio.space/companies/artelo-biosciences/) NASDAQ: ARTL - [Jupiter Neurosciences](https://aibio.space/companies/jupiter-neurosciences/) NASDAQ: JUNS ### Also on NASDAQ - [Orchestra BioMed Holdings](https://aibio.space/companies/orchestra-biomed/) OBIO - [Tectonic Therapeutic](https://aibio.space/companies/tectonic-therapeutic/) TECX - [IRulya Therapeutics](https://aibio.space/companies/irulya-therapeutics/) IRLA - [Regeneron Pharmaceuticals](https://aibio.space/companies/regeneron-pharmaceuticals/) REGN - [Zevra Therapeutics](https://aibio.space/companies/zevra-therapeutics/) ZVRA - [VivoSim Labs, INC.](https://aibio.space/companies/vivosim-labs/) VIVS ## What Allarity Therapeutics does Allarity Therapeutics, Inc. is a clinical-stage precision medicine pharmaceutical company developing novel anti-cancer therapeutics for patients with high unmet medical need. It was founded on its Drug Response Predictor (DRP) platform, which defines gene expression signatures in cancer cells that predict sensitivity to a specific cancer therapeutic, so that patients likely to benefit can be identified from tumor biopsies. The company is now focused on stenoparib, a novel dual inhibitor of PARP1/2 and tankyrases, which it in-licensed with exclusive worldwide rights from Eisai Pharmaceuticals. Stenoparib has been explored in a Phase 2 clinical trial in patients with advanced, recurrent ovarian cancer who were pre-selected using the stenoparib DRP. A new clinical protocol was initiated in June 2025 and is enrolling patients randomized into two dose levels. The company is also developing the stenoparib DRP as a companion diagnostic to select patients for stenoparib treatment. Its other assets, including dovitinib, Irofulven and LiPlaCis, were terminated and are no longer part of its portfolio. | Product or program | What it is | Stage | |---|---|---| | Stenoparib | Dual PARP1/2 and tankyrase inhibitor for advanced recurrent ovarian cancer | Phase 2 trial ongoing | | Stenoparib DRP | Gene expression companion diagnostic to select patients for stenoparib | in development | Summarised from the company's [10-K filed Mar 30, 2026](https://www.sec.gov/Archives/edgar/data/1860657/000143774926010310/allr20251231_10k.htm). ## Allarity Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$6.6 million](https://www.sec.gov/Archives/edgar/data/1860657/000143774926010310/) | [$6.1 million](https://www.sec.gov/Archives/edgar/data/1860657/000143774926010310/) | | Net income (loss) | [-$11.2 million](https://www.sec.gov/Archives/edgar/data/1860657/000143774926010310/) | [-$24.5 million](https://www.sec.gov/Archives/edgar/data/1860657/000143774926010310/) | | Cash from operations | [-$14.8 million](https://www.sec.gov/Archives/edgar/data/1860657/000143774926010310/) | [-$17.4 million](https://www.sec.gov/Archives/edgar/data/1860657/000143774926010310/) | | Cash and equivalents | [$14.7 million](https://www.sec.gov/Archives/edgar/data/1860657/000143774926027830/) | [$19.5 million](https://www.sec.gov/Archives/edgar/data/1860657/000143774926010310/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $17.0 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Allarity Therapeutics Has Allarity Therapeutics raised money recently? Our latest story on this, dated Sep 22, 2025: "Allarity Therapeutics agrees to $2.5 million private placement of shares and pre-funded warrants". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/allarity-therapeutics-agrees-2-5-million-private-placement-7-5-million/). Has Allarity Therapeutics received a Nasdaq deficiency notice? Our latest story on this, dated Aug 14, 2025: "Allarity Therapeutics delays quarterly report while auditors finish review". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/allarity-therapeutics-delays-quarterly-report-while-auditors-finish/). What is the ticker symbol of Allarity Therapeutics? Allarity Therapeutics, Inc. trades under the ticker ALLR on NASDAQ. Where is Allarity Therapeutics listed? Allarity Therapeutics, Inc. is listed on NASDAQ. What is the SEC CIK of Allarity Therapeutics? The SEC Central Index Key (CIK) for Allarity Therapeutics, Inc. is 1860657. Its filings are on SEC EDGAR. How many shares does Allarity Therapeutics have outstanding? 15,910,724 shares as of 2026-08-14, per the cover page of its 10-Q filed 2026-08-14. Which country or territory is Allarity Therapeutics listed under? Our directory records Allarity Therapeutics, Inc. under United States. What does Allarity Therapeutics do? Our directory classifies Allarity Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Allarity Therapeutics? The ISIN recorded for Allarity Therapeutics, Inc. is US0167445008. Does aibio.space cover Allarity Therapeutics? aibio.space lists Allarity Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Allarity Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What does Allarity Therapeutics develop? Allarity Therapeutics, Inc. is a clinical-stage precision medicine pharmaceutical company developing novel anti-cancer therapeutics for patients with high unmet medical need. It was founded on its Drug Response Predictor (DRP) platform, which defines gene expression signatures in cancer cells that predict sensitivity to a specific cancer therapeutic, so that patients likely to benefit can be identified from tumor biopsies. What is Stenoparib from Allarity Therapeutics? Stenoparib: Dual PARP1/2 and tankyrase inhibitor for advanced recurrent ovarian cancer Stage: Phase 2 trial ongoing. What is Stenoparib DRP from Allarity Therapeutics? Stenoparib DRP: Gene expression companion diagnostic to select patients for stenoparib Stage: in development. Is Allarity Therapeutics profitable? Allarity Therapeutics, Inc. reported a net loss of $11.2 million for the fiscal year ended Dec 31, 2025, and used $14.8 million of cash in operations, per its annual report to the SEC. ## Investor discussion: Allarity Therapeutics Members talk about Allarity Therapeutics (ALLR). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Allarity Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-10-30 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02). [Source](https://www.sec.gov/Archives/edgar/data/1860657/000121390026114380/ea0310280-8k_allarity.htm) 2. 2026-10-30 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1860657/000121390026114390/ea0310280-424b5_allarity.htm) 3. 2026-03-06 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1860657/000121390026024339/ea0279478-8k_allarity.htm) 4. 2026-02-12 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1860657/000121390026015583/ea0276263-s3_allarity.htm) 5. 2026-01-29 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1860657/000121390026009158/ea0273806-424b5_allarity.htm) 6. 2025-12-03 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1860657/000121390025117592/ea0260587-s3_allarity.htm) 7. 2025-09-22 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1860657/000121390025090197/ea0258310-8k_allarity.htm) 8. 2025-08-14 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1860657/000121390025076643/ea0253333-nt10q_allarity.htm) 9. 2025-06-17 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1860657/000143774925020652/allr20250617_8k.htm) 10. 2025-05-09 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1860657/000143774925015780/allr20250128_10q.htm) 11. 2025-03-04 Financings Announced a share repurchase program. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1860657/000143774925006012/allr20250303_8k.htm) 12. 2025-02-27 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1860657/000143774925005341/allr20250226_8k.htm) 13. 2025-01-30 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1860657/000143774925002184/allr20250117_8k.htm) 14. 2024-11-14 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1860657/000143774924035314/allr20240930_10q.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ALLR on TradingView](https://www.tradingview.com/symbols/NASDAQ-ALLR/). ## SEC filings and registration - **SEC name**: Allarity Therapeutics, Inc. - **CIK**: 1860657 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: ALLR (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 24 SCHOOL ST., 2ND FLOOR, BOSTON, MA, 02108 - **Phone**: 401-426-4664 - **Shares outstanding**: 15,910,724 as of 2026-08-14 (10-Q filed 2026-08-14) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1860657/000121390026105457/ea0307298-8k_allarity.htm) filed 2026-10-01 - [8-K](https://www.sec.gov/Archives/edgar/data/1860657/000121390026104317/ea0306873-8k_allarity.htm) filed 2026-09-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1860657/000121390026100350/ea0305570-8k_allarity.htm) filed 2026-09-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1860657/000121390026099576/ea0305408-8k_allarity.htm) filed 2026-09-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1860657/000121390026090183/ea0302157-8k_allarity.htm) filed 2026-08-14 - [10-Q](https://www.sec.gov/Archives/edgar/data/1860657/000143774926027830/allr20260630_10q.htm) filed 2026-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1860657/000121390026073998/ea0296615-8k_allarity.htm) filed 2026-07-01 - [8-K](https://www.sec.gov/Archives/edgar/data/1860657/000121390026070382/ea0295409-8k_allarity.htm) filed 2026-06-22 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001860657), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Allarity Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ALLR, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Allarity Therapeutics, Inc. - **Ticker**: ALLR - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US0167445008 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ALLR/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/allarity-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Allarity Therapeutics (ALLR) news: offering and Nasdaq notice", 2026-10-31, https://aibio.space/companies/allarity-therapeutics/